Investigation of the effect of vaccines made in the last year in individuals aged 65 and over on COVID-19 transmission and course

Aim: A lot of research is being done to prevent the rapid spread of COVID-19 and to protect people from this disease. In this study, it was aimed to investigate whether the vaccines administered to individuals aged 65 and over in the last year have an effect on the transmission of COVID-19 to these individuals and on the clinical course of the infected individuals. Material and Method: Our research was conducted as an Observational Descriptive study. The questionnaire we prepared was used in the research. The data of our research were obtained between the dates of 09.12.2020-28.02.2021 by calling individuals aged 65 and over by phone or by making a face-to-face questionnaire at Family Health Centers. Randomly selected, meeting the inclusion criteria; 520 people who had COVID-19 and 520 people who did not have COVID-19 participated in our research. The data obtained from the questionnaire, which includes the sociodemographic data of the participants, their chronic diseases, tobacco products and alcohol use, the vaccines they have had in the last year and the questions about COVID-19, were analyzed using the IBM SPSS Statistics 26 package program. Results: Randomly selected, with ages between 65 and 98; 520 (50,0%) had COVID-19, 520 (50,0%) did not have COVID-19, 499 (48,0%) were men, 541 (52,0%) were women total 1040 people participated in our research. While 317 (30.5%) of the participants had any vaccination in the last year, 723 (69.5%) did not. 100 (9.6%) had Influenza Vaccine, 254 (24.4%) Conjugated Pneumococcal Vaccine (KPA13) and 11 (1.1%) other vaccines. Conclusion: It was found statistically significant that those who had KPA13 in the last year had less COVID-19 than those who did not. (Pearson CI-square, p <0,001) Although it was observed that those who had Influenza Vaccine in the last year had less COVID-19 compared to those who did not, it was not statistically significant. (Pearson CI-square, p> 0,05) Key Words: COVID-19, Vaccines, KPA13, Influenza Vaccine